Transdermal Drug Delivery Systems (TDDS) are used to administer medications through the skin to the circulatory system. TDDS deliver drugs at a predetermined rate and maintain sufficient concentrations clinically to ensure a quick response. TDD devices are commonly used for pain management and during treatments of chronic diseases like cardiovascular diseases, cancer, and diabetes.

The transdermal drug delivery systems market is growing rapidly over recent years, mainly due to the growing geriatric population and the prevalence of chronic diseases. Moreover, rapid advancements and increasing adoption of transdermal drug delivery technology are expected to accelerate the growth of the market during the forecast period.

Market Research Future (MRFR) states that the global transdermal drug delivery systems market had created a value of USD 5,400.2 MN in 2017. This market value is expected to appreciate at a double-digit CAGR of 11.8% throughout the forecast period (2018 – 2023). Increasing cancer cases is a major driving force pushing upmarket growth.

Get Sample Copy of Report @ https://www.marketresearchfuture.com/sample_request/7545

Furthermore, the increasing occurrence of needle-stick injuries and growing uses of biologics are driving market growth. Substantial investments drawn in the R&D to develop advanced TDD systems are boosting the growth of the market, significantly. Additionally, spreading awareness, improving outcomes & patients’ experience, and beneficial reimbursement policies impact the market growth, positively.

Major Players:

Players leading the transdermal drug delivery systems market include Mylan N.V., Hisamitsu Pharmaceutical Co., Inc., Novartis International AG, Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Endo Pharmaceuticals Inc., UCB S.A., Pfizer Inc., Allergan plc., Actelion Pharmaceuticals Ltd, and Noven Pharmaceuticals, Inc., among others.

Segmentation

The global transdermal (percutaneous) drug delivery systems market has been segmented into product, technology, and application.

By Product, the market has been divided into transdermal patches and transdermal semisolids. The transdermal patches segment is further categorized into microneedle patches, drug-in-adhesive patches, matrix patches, and reservoir membrane patches. On the other hand, the transdermal semisolids segment is segmented into sprays, gels, and ointments. The transdermal patches segment had held the majority of the market in 2017 due to its benefits of reduced dosing frequency, lower adverse events, improved bioavailability, enhanced patient compliance (non-invasive nature), and painless application.
Based on Technology, the market has been divided into thermal, electric current, ultrasound, iontophoresis, electroporation, microporation, and others.
By Application, the market caters to hormone replacement therapy, smoking cessation, contraception, pain management, cardiovascular diseases, central nervous system disorders, and others.
Regional Analysis

The global transdermal (percutaneous) drug delivery systems market has been segmented by region into the Americas, Europe, Asia Pacific (APAC), and the Middle East & Africa (MEA).

Geographically, in 2017, the Americas dominated the global TDDS market due to the presence of major market players (Pfizer Inc., and Johnson & Johnson Services, Inc.) and developed healthcare infrastructure. Increased investments in research activities related to transdermal drug delivery systems, a surge in surgeries, and high adoption of TDDS systems in the US and Canada.

Europe would follow the Americas in the global transdermal (percutaneous) drug delivery systems market owing to stellar advances in the pharmaceutical industry. The growth is foster due to the proximity of pharma heavyweights such as Hisamitsu Pharmaceutical Co., Inc., Novartis International AG, Mylan N.V., Boehringer Ingelheim International GmbH, and Allergan plc.

Get Access Full Report @ https://www.marketresearchfuture.com/reports/transdermal-drug-delivery-systems-market-7545

APAC is expected to generate maximum revenue for the global TDDS market owing to the growing elderly population and the rising prevalence of chronic diseases. India, China, and Japan are likely to contribute to the growth of the APAC transdermal drug delivery systems marekt throughout the forecast period. For instance, the coronary artery disease among Asian Indians (CADI) Research Foundation had reports of hypertension being highly prevalent disease in India. The number is estimated to reach to 214 million by 2025. This can be prove to be lucrative for manufacturers of TDDS.

The MEA region would register a modest market growth rate during the forecast period. Introduction of new healthcare models and modernization of infrastructure in the Gulf Cooperation Council (GCC) countries and Sub-Saharan African countries can induce demand for TDDS in the region.